Fig 2: Phenotype of induced MDSCs and suppressing ability. (A) Flow analysis of the cell-surface expression of CD33, CD11b, CD14, CD15 and HLA-DR on in vitro induced MDSCs with IL6/GM-CSF for 7 days. (B) and (D) The ability of suppressing T cells proliferation in M-MDSCs at ratio of 1:4 as determined by CFSE label assay and secretion of IFN-? by ELISA. (C) Gene expression of relative suppressive mechanisms in MDSCs such as VEGF, NOX2, TGF-ß, PD-L1, ARG1, PD-L2 in induced M-MDSCs as determined by reverse transcription-quantitative PCR. (E) Percentage of positive p-STAT3 and PDL1 cells in induced M-MDSCs. ***P<0.0001. MDSCs, myeloid-derived suppressor cells; HLA, human leukocyte antigen; GM-CSF, granulocyte-macrophage colony-stimulating factors; M-MDSCs, monocytic MDSCs; CFSE, carboxyfluorescein succinimidyl ester; NOX2, NADPH oxidase 2; PD-L, programmed death ligand; ARG1, arginase 1; p-, phosphorylated.